Barclays Forecasts Strong Price Appreciation for Cooper Companies (NASDAQ:COO) Stock

Cooper Companies (NASDAQ:COO) had its target price upped by equities researchers at Barclays from $98.00 to $103.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical device company’s stock. Barclays‘s target price suggests a potential upside of 33.68% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on the company. Weiss Ratings upgraded Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, January 12th. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a research report on Friday, December 5th. Stifel Nicolaus set a $95.00 price target on Cooper Companies and gave the stock a “buy” rating in a research report on Friday, December 5th. William Blair raised shares of Cooper Companies to a “strong-buy” rating in a research report on Friday, January 30th. Finally, Needham & Company LLC raised their target price on shares of Cooper Companies from $99.00 to $101.00 and gave the company a “buy” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.86.

Cooper Companies Stock Performance

COO stock traded down $3.15 during trading hours on Friday, hitting $77.05. 1,462,397 shares of the stock were exchanged, compared to its average volume of 1,977,256. Cooper Companies has a 12 month low of $61.78 and a 12 month high of $89.83. The company has a current ratio of 1.89, a quick ratio of 1.13 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $15.03 billion, a P/E ratio of 40.98, a P/E/G ratio of 2.34 and a beta of 1.02. The company has a 50-day simple moving average of $82.23 and a two-hundred day simple moving average of $75.95.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, March 5th. The medical device company reported $1.10 EPS for the quarter, beating the consensus estimate of $1.03 by $0.07. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. Cooper Companies’s revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.92 earnings per share. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. On average, analysts forecast that Cooper Companies will post 3.98 earnings per share for the current fiscal year.

Insider Transactions at Cooper Companies

In related news, insider Holly R. Sheffield bought 1,230 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were purchased at an average price of $80.75 per share, with a total value of $99,322.50. Following the completion of the purchase, the insider owned 39,052 shares in the company, valued at $3,153,449. This represents a 3.25% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Cynthia L. Lucchese purchased 1,784 shares of the company’s stock in a transaction dated Monday, December 22nd. The stock was purchased at an average price of $84.06 per share, with a total value of $149,963.04. Following the completion of the purchase, the director directly owned 9,445 shares in the company, valued at $793,946.70. The trade was a 23.29% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 16,014 shares of company stock valued at $1,304,416. Corporate insiders own 2.08% of the company’s stock.

Institutional Investors Weigh In On Cooper Companies

Several hedge funds have recently added to or reduced their stakes in COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Cooper Companies by 48.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after purchasing an additional 7,363 shares during the period. Assetmark Inc. raised its stake in Cooper Companies by 357.8% during the second quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock worth $44,000 after buying an additional 483 shares during the last quarter. Resona Asset Management Co. Ltd. boosted its position in Cooper Companies by 7.9% during the second quarter. Resona Asset Management Co. Ltd. now owns 67,988 shares of the medical device company’s stock valued at $4,838,000 after acquiring an additional 4,976 shares during the last quarter. Twin Capital Management Inc. raised its position in shares of Cooper Companies by 4.8% in the 2nd quarter. Twin Capital Management Inc. now owns 8,074 shares of the medical device company’s stock worth $575,000 after acquiring an additional 372 shares in the last quarter. Finally, Bastion Asset Management Inc. acquired a new position in shares of Cooper Companies in the 2nd quarter valued at about $8,784,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 results beat and company raised guidance — Cooper reported $1.10 EPS (above consensus) and ~6.2% revenue growth; management raised EPS and free?cash?flow guidance for 2026, highlighting momentum in MyDay and MiSight contact lenses. CooperCompanies Announces First-Quarter 2026 Results
• Positive Sentiment: Analyst upgrade and price?target lift — Needham raised its price target to $101 and kept a Buy rating, providing explicit upside catalysts tied to product momentum and guidance. Benzinga
• Positive Sentiment: Insider buying and operational metrics — Recent reported insider purchases and improved operating leverage (higher operating margin, stronger cash from ops) support confidence in execution. The Cooper Companies (COO) Stock Falls on Q1 2026 Earnings
• Neutral Sentiment: Product R&D / clinical messaging at NCC 2026 — CooperVision highlighted research supporting long?term comfort for contact lens wearers, which helps the narrative but is a longer?term commercial story. NCC 2026: CooperVision Research Supports a Lifetime of Clear, Comfortable Contact Lens Wear
• Neutral Sentiment: Strategic review flagged by company/press coverage — Reports note a strategic review is in focus; this can be neutral-to-positive depending on outcomes (asset sales, portfolio moves). Cooper Companies earnings up next: Strategic review in focus
• Negative Sentiment: Analyst caution on core vision growth — Morgan Stanley kept a Hold and $83 target, citing sluggish core CooperVision growth that could limit upside despite fertility and specialty lens gains. Cooper Companies: Solid Earnings and Fertility Recovery Offset by Sluggish Core Vision Growth, Warranting a Hold Rating
• Negative Sentiment: Valuation and mixed top?line reads — COO trades at a premium multiple (P/E ~42.7) and revenue growth is modest; if CooperVision growth stays tepid, valuation could cap near?term gains.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.